Dissecting the In Vitro Efficacy of Octreotide and Cabergoline in GH- and GH/PRL-Secreting Pituitary Tumors
The Journal of Clinical Endocrinology & Metabolism · 2023
DOI: 10.1210/clinem/dgac675 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Journal of Clinical Endocrinology & Metabolism, 2023. Verfasst von Federico Gatto und 8 weiteren Autor:innen. Beteiligte Einrichtung: Endocrinology Unit, IRCCS Ospedale Policlinico San Martino, 16132 Genova, Italy. Hauptthemen laut MEDLINE: Pituitary Neoplasms, Acromegaly, Human Growth Hormone. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 49 Literaturangaben.
Abstract (Originalsprache)
Context
Cabergoline (CAB) is an off-label medical therapy for acromegaly, overshadowed by first-generation somatostatin receptor ligands, eg, octreotide (OCT).
Objective
This was a head-to-head comparison between OCT and CAB in inhibiting growth hormone (GH) secretion in primary cultures of GH- and GH/prolactin (PRL)-secreting tumors; we also investigated the role of somatostatin (SST) and dopamine type 2 (D2R) receptor expression.
Methods
We evaluated the antisecretory effect of OCT and CAB, together with receptor mRNA expression, in 23 tumor cultures obtained from acromegaly patients referred to the Erasmus Medical Center (Rotterdam, The Netherlands). GH concentrations in cell culture media were determined after 72-hour OCT and CAB treatment (10 nM).
Results
OCT showed a slightly higher efficacy compared with CAB (GH decrease −39.5% vs −32.5%, P = 0.079). The effect of the 2 drugs was superimposable in GH/PRL co-secreting tumors (−42.1% vs −44.8%), where SST1 and D2R had a higher expression compared with the pure GH-secreting tumors (P = 0.020 and P = 0.026). OCT was more effective than CAB in 8/23 cultures, while CAB was more effective than OCT in 3/23 (CAB+ group). In CAB+ tumors, SST1 expression was higher compared with the other groups (P = 0.034). At receiver operating characteristic (ROC) curve analysis, SST1 and D2R discriminated between GH and GH/PRL co-secretion (AUC 0.856, P = 0.013; AUC 0.822, P = 0.024). SST1 was the best predictor of CAB response (≥50% GH reduction, AUC 0.913, P = 0.006; 80% sensitivity, 94% specificity).
Conclusion
OCT is 5% to 10% more effective than CAB in vitro. SST1 mRNA expression can represent a reliable marker of GH/PRL co-secreting tumors showing a preferential response to CAB treatment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Endocrinology Unit, IRCCS Ospedale Policlinico San Martino, 16132 Genova, Italy.
- Department of Internal Medicine, Division of Endocrinology, Erasmus MC, 3015 GD, Rotterdam, The Netherlands.
- Pituitary Center Rotterdam, Erasmus MC, 3015 GD, Rotterdam, The Netherlands.
- Endocrinology Unit, Department of Internal Medicine and Medical Specialties, University of Genoa, 16132 Genoa, Italy.
ORCID-Profile: Federico Gatto, Richard A Feelders, Diego Ferone
Zitieren
APA
Gatto, F., Feelders, R. A., van Koetsveld, P. M., Dogan, F., Neggers, S. J. C. M. M., van der Lelij, A. J., Amarù, J., Ferone, D., & Hofland, L. J. (2023). Dissecting the In Vitro Efficacy of Octreotide and Cabergoline in GH- and GH/PRL-Secreting Pituitary Tumors. The Journal of Clinical Endocrinology & Metabolism. https://doi.org/10.1210/clinem/dgac675
Vancouver
Gatto F, Feelders RA, van Koetsveld PM, Dogan F, Neggers SJCMM, van der Lelij AJ, et al. Dissecting the In Vitro Efficacy of Octreotide and Cabergoline in GH- and GH/PRL-Secreting Pituitary Tumors. The Journal of Clinical Endocrinology & Metabolism. 2023. doi:10.1210/clinem/dgac675
BibTeX
@article{Gatto2023,
author = {Gatto, Federico and Feelders, Richard A and van Koetsveld, Peter M and Dogan, Fadime and Neggers, Sebastian J C M M and van der Lelij, Aart-Jan and Amarù, Jessica and Ferone, Diego and Hofland, Leo J},
title = {Dissecting the In Vitro Efficacy of Octreotide and Cabergoline in GH- and GH/PRL-Secreting Pituitary Tumors},
journal = {The Journal of Clinical Endocrinology & Metabolism},
year = {2023},
doi = {10.1210/clinem/dgac675}
}
EUVIMED